TICKERNERD
Menu
IMUXIMUXHealthcare · Biotechnology

IMUX Stock Forecast: Immunic, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
−3.55% on the day

The 12 Wall Street analysts covering Immunic, Inc. hold a median 12-month price target of $30 — +162.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$155.8M
Ticker Nerd rank
34 / 100
Median analyst target
$30
Analysts covering
12
Revenue$0.0
Operating income−$35.3M
Net income−$34.1M
Free cash flow−$31.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.5%
1M
−26.2%
YTD
+113.9%
1Y
+34.0%
From 52W high
−32.4%
From 52W low
+123.9%
$5
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMUX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immunic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Size
71
Revisions
58
Momentum
57
Accruals
46
Growth
40
Issuance
36
Quality
18
Value
15

Volatility (78): The share price has been relatively steady.

Value (15): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMUX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMUX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26IMUXHigh $85Median $30Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $22Median $30High $85

The green dot is the last close — the median target sits +162.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.ReiteratesBuy$22
10 Sept 2026WedbushReiteratesOutperform$45
17 Aug 2026WedbushInitiatesOutperform—
17 Aug 2026WedbushInitiatesOutperform$45
22 May 2026B. Riley SecuritiesMaintainsBuy$40 → $27
22 May 2026B. Riley SecuritiesMaintainsBuy—
30 Apr 2026HC Wainwright & Co.MaintainsBuy—
17 Apr 2026StifelInitiatesBuy—
15 Apr 2026D. Boral CapitalDowngradeHold—
24 Mar 2026GuggenheimInitiatesBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Feb 2026D. Boral CapitalMaintainsBuy—
9 Feb 2026HC Wainwright & Co.ReiteratesBuy—
7 Jan 2026D. Boral CapitalMaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
29 Sept 2025Chardan CapitalInitiatesBuy—
26 Sept 2025HC Wainwright & Co.ReiteratesBuy—
25 Sept 2025D. Boral CapitalMaintainsBuy—
8 Aug 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMUX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IMUX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Immunic, Inc. returned +34.0% against +17.5% for the S&P 500, dividends included.

IMUX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26IMUXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMUX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
3
Fundamentals

Immunic, Inc. (IMUX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
1.2×

Cheaper than 67% of US stocks

EV / EBITDA
−0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−138.2%

Higher than 10% of US stocks

Return on assets
−66.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immunic, Inc. (IMUX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immunic, Inc. has a market value of $155.8M and an enterprise value of $1.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$111.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$88.0M.

  • Shares outstanding: 13.6M.

  • Trailing P/E: −1.8×; forward P/E: −4.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Immunic, Inc. employs 100 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

IMUX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMUXImmunic, Inc.$155.8M
34
SPRBSpruce Biosciences, Inc.$154.3M
27
CDXSCodexis, Inc.$157.6M
64
HUMAHumacyte, Inc.$153.0M
17
OTLKOutlook Therapeutics, Inc.$160.7M
4
CRBPCorbus Pharmaceuticals Holdings, Inc.$150.4M
23
CNTNCanton Strategic Holdings, Inc.$162.7M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immunic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMUX news & analysis

Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript

Seeking Alpha · 11 Sept 2026neutral

Immunic, Inc. discussed its research and development advances and future directions in relapsing multiple sclerosis during a transcript, as covered by Seeking Alpha. The discussion focuses on the company's ongoing R&D efforts in this indication.

Why it matters — IMUX watchers would want to follow the company's R&D progress in relapsing multiple sclerosis, a key area of its pipeline.

Immunic to host virtual relapsing MS R&D Day on September 9

Proactive Investors · 2 Sept 2026neutral

Immunic announced it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9. The event will feature management including the CEO, CMO, CSO, and president/COO, ahead of topline results from its Phase 3 ENSURE trials expected by the end of 2026.

Why it matters — The R&D day gives Immunic watchers an opportunity to hear management discuss its relapsing MS program in detail as the company approaches the anticipated Phase 3 ENSURE topline results.

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

PRNewsWire · 2 Sept 2026neutral

Immunic, Inc. announced it will host a virtual research and development day focused on relapsing multiple sclerosis on Wednesday, September 9, 2026, at 11:00 am ET. The event is scheduled to be held virtually.

Why it matters — The R&D day will provide IMUX watchers with an opportunity to learn more about the company's pipeline activities related to relapsing multiple sclerosis.

Immunic Appoints Chitrang Davé as Chief Data and Digital Officer

PRNewsWire · 1 Sept 2026positive

Immunic, Inc. announced the appointment of Chitrang Davé as its new Chief Data and Digital Officer, a newly created C-suite role effective September 1, 2026. The appointment reflects the company's focus on building a commercial-ready data ecosystem in preparation for a potential NDA submission and commercialization.

Why it matters — IMUX watchers would care because adding a dedicated data and digital leader signals the company is advancing its infrastructure ahead of a potential regulatory submission and commercialization for its neurologic disease therapies.

Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating

Seeking Alpha · 25 Aug 2026positive

Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. The oral therapy's differentiated mechanism of action positions it as a potential major player in the MS market, which is projected to reach roughly $22 billion in 2026 revenues.

Why it matters — An IMUX watcher would care because the article highlights the company's late-stage MS pipeline as a potent, under-the-radar opportunity in a large and growing market.

FAQ

Frequently asked questions about IMUX stock

What is the IMUX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Immunic, Inc. have a median 12-month price target of $30, with estimates ranging from $22 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMUX stock a buy right now?

Of the 12 analysts covering Immunic, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunic, Inc. 34 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMUX?

As at 12 Sept 2026, Immunic, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

Will IMUX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +162.7% from the last close, and Ticker Nerd's factor model ranks Immunic, Inc. 34 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMUX stock forecast for 2030?

No analyst covering Immunic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMUX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $85 over the next 12 months.

How has IMUX stock performed over the past year?

Immunic, Inc. returned +34.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immunic, Inc. do?

Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases.

What is the latest news on IMUX?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript". Immunic, Inc. discussed its research and development advances and future directions in relapsing multiple sclerosis during a transcript, as covered by Seeking Alpha. The discussion focuses on the company's ongoing R&D efforts in this indication.

Company

About Immunic, Inc.

Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis. The company’s lead program, IMU-838, is being studied in late-stage and mid-stage clinical development, while IMU-856 is being advanced for gastrointestinal disorders linked to intestinal barrier dysfunction. Immunic also maintains earlier-stage research programs in immune-mediated diseases. With operations in the United States and Germany, Immunic, Inc. plays a role in the clinical-stage biopharmaceutical market by advancing oral, mechanism-based therapies aimed at complex inflammatory conditions.

CEO Mr. Erik Lundgren · 100 employees · United States · https://imux.com